Portal de Periódicos da CAPES

Cytotoxic Drugs in the Treatment of Skin Disease

1991; Wiley; Volume: 30; Issue: 5 Linguagem: Inglês

10.1111/j.1365-4362.1991.tb03868.x

1365-4632

Ronald P. Rapini,

Cutaneous lymphoproliferative disorders research

International Journal of DermatologyVolume 30, Issue 5 p. 313-322 Cytotoxic Drugs in the Treatment of Skin Disease Ronald P Rapini M.D., Corresponding Author Ronald P Rapini M.D. Departments of Dermatology and Pathology, University of Texas Medical School, Houston, Texas.Address correspondence to: Ronald P. Rapini, M.D., Associate Professor of Dermatology and Pathology, University of Texas Medical School, 6431 Fannin #1.204, Houston, TX 77030.Search for more papers by this author Ronald P Rapini M.D., Corresponding Author Ronald P Rapini M.D. Departments of Dermatology and Pathology, University of Texas Medical School, Houston, Texas.Address correspondence to: Ronald P. Rapini, M.D., Associate Professor of Dermatology and Pathology, University of Texas Medical School, 6431 Fannin #1.204, Houston, TX 77030.Search for more papers by this author First published: May 1991 https://doi.org/10.1111/j.1365-4362.1991.tb03868.xCitations: 17AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Harris CC. The carcinogenicity of anticancer drugs: a hazard in man. Cancer. 1976; 37: 1014– 1023. 2 Penn I. Second malignant neoplasms associated with immuno- suppressive medications. Cancer. 1976; 37: 1024– 1032. 3 Penn I. Immunosuppression and skin cancer. Clin Plast Surg. 1980; 7: 361– 368. 4 McDonald CJ. Cytotoxic agents for use in dermatology: Part 1. J Am Acad Dermatol. 1985; 12: 753– 775. 5 McDonald CJ. Use of cytotoxic drugs in dermatologic diseases: Part II. J Am Acad Dermatol. 1985; 12: 965– 975. 6 Dantzig PI. Immunosuppressive and cytotoxic drugs in dermatology. Arch Dermatol. 1974; 110: 393– 406. 7 Schwartz RS, Gowans JDC. Guidelines for the use of cytotoxic drugs in rheumatic diseases (letter). Arthritis Rheum. 1971; 14: 134. 8 Steinberg AD, Plotz PH, Wolff SM, Wong VG, Agus SG, Decker JL. Cytotoxic drugs in the treatment of nonmalignant disease. Ann Intern Med. 1972; 76: 619– 642. 9 Whitehouse JMA. Cytotoxic drugs for non-neoplastic disease. Br Med J. 1983; 287: 79– 80. 10 Gupta AK, Brown MD, Ellis CN, et al. Cyclosporine in dermatology. J Am Acad Dermatol. 1989; 21: 1245– 1256. 11 Roenigk HH, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis; revised guidelines. J Am Acad Dermatol. 1988; 19: 145– 156. 12 Moschella SL. Chemotherapy used in dermatology. Cutis. 1977; 19: 603– 612. 13 Gomez EC, Menendez L, Frost P. Efficacy of mycophenolic acid for the treatment of psoriasis. J Am Acad Dermatol. 1979; 1: 531– 537. 14 Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990; 322: 281– 285. 15 Nethercott J, Lester RS. Azathioprine therapy in incomplete Behcet's syndrome. Arch Dermatol. 1974; 110: 432– 434. 16 Arbesfeld SJ, Kurban AK. Behcet's disease; new perspectives on an enigmatic syndrome. J Am Acad Dermatol. 1988; 19: 767– 779. 17 Benson M, Aldo M. Azathioprine therapy in polymyositis. Arch Intern Med. 1973; 132: 547– 551. 18 Niakan E, Pitner SE, Whitaker JN, et al. Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis. Neurology. 1980; 30; 286– 290. 19 Miller G, Heckmatt JZ, Dubowitz V. Drug treatment of juvenile dermatomyositis. Arch Dis Child. 1983; 58: 445– 450. 20 Ansell BM. Management of polymyositis and dermatomyositis. Clin Rheum Dis. 1984; 10: 205– 213. 21 Morrison JGL, Schulz EJ. Treatment of eczema with cyclo phosphamide and azathioprine. Br J Dermatol. 1978; 98: 203– 207. 22 Freeman K, Hewitt M, Warin AP. Two cases of distinctive exudative discoid and lichenoid chronic dermatosis of Sulzberger and Garbe responding to azathioprine. Br J Dermatol. 1984; 111: 215– 220. 23 Corley CC Jr, Lessner HE, Larsen WE. Azathioprine therapy of “autoimmune” diseases. Am J Med. 1966; 41: 404– 412. 24 Sztejnbok M, Stewart A, Diamond H, et al. Azathioprine in the treatment of systemic lupus erythematosus; a controlled study. Arthritis Rheum. 1971; 14: 639– 645. 25 Cade R, Spooner G, Schlein F, et al. Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron. 1973; 10: 37– 56. 26 Donadio JV, Holley KE, Wagoner RD, et al. Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Arthritis Rheum. 1974; 17: 573– 581. 27 Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Ann Intern Med. 1975; 83: 597– 605. 28 Sabbour MS, Osman LM. Comparison of chlorambucil, azathioprine, or cyclophosphamide combined with corticosteroids in the treatment of lupus nephritis. Br J Dermatol. 1979; 100: 113– 125. 29 Dinant HJ, Decker JL, Klippel JH, et al. Alternate modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med. 1982; 96: 728– 736. 30 Tsokos GC, Caughman SW, Klippel JH. Successful treatment of generalized discoid skin lesions with azathioprine; its use in a patient with systemic lupus erythematosus. Arch Dermatol. 1985; 121: 1323– 1325. 31 Shehade S. Successful treatment of generalized discoid skin lesions with azathioprine (letter). Arch Dermatol. 1986; 122: 376– 377. 32 Ashinoff R, Werth VP, Franks AG Jr. Resistant discoid lupus erythematosus of palms and soles; successful treatment with azathioprine. J Am Acad Dermatol. 1988; 19: 961– 965. 33 Greaves MW, Burton JL, Marks J, et al. Azathioprine in the treatment of bullous pemphigoid. Br Med J. 1971; 1: 144– 145. 34 Dave VK, Vickers CFH. Azathioprine in the treatment of muco-cutaneous pemphigoid. Br J Dermatol. 1974; 90: 183– 186. 35 Burton JL, Greaves MW. Azathioprine for pemphigus and pemphigoid; a four year follow up study. Br J Dermatol. 1974; 91: 103– 109. 36 Burton JL, Harman RMM, Peachey RDG, et al. A controlled study of azathioprine in the treatment of pemphigoid. Br J Der matol. 1978: 99(suppl 16). 37 Burton JL, Harman RRM, Peachey RDG, et al. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J. 1978; 2: 1190– 1191. 38 Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid; clinical and immunologic follow-up after successful therapy. Arch Dermatol. 1977; 113: 1043– 1046. 39 Levene GM. The treatment of pemphigus and pemphigoid. Clin Exp Dermatol. 1982; 7: 643– 652. 40 Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol. 1983; 96: 453– 459. 41 Jablonska S, Chorzelski T. Immunosuppressants in the treat ment of pemphigus. BrJ Dermatol. 1970; 83: 315– 323. 42 Roenigk HH, Deodhar S. Pemphigus treatment with azathio- pdne: clinical and immunologic correlation. Arch Dermatol. 1973; 107: 353– 357. 43 Faber WR, Neumann HA, Flinterman J. Persistent vegetating and keratotic lesions in patients with pemphigus vulgaris during immunosuppressive therapy. Br J Dermatol. 1983; 109: 459– 463. 44 Roed-Peterson J, Thomsen K. Azathioprine in the treatment of airborne contact dermatitis from compositae oleoresins and sensitivity to UVA. Acta Derm Venereol. 1980; 60: 275– 276. 45 Leigh IM, Hawk JL. Treatment of chronic actinic dermatitis with azathioprine. Br J Dermatol. 1984; 110: 691– 695. 46 Murphy GM, Maurice PDL, Norris PG, et al. Azathioprine treatment in chronic actinic dermatitis: a double-blind con trolled trial with monitoring of exposure to ultraviolet radiation. Br J Dermatol. 1989; 121: 639– 646. 47 Toonstra J, Henquet CJM, van Weelden H, et al. Actinic reticuloid. J Am Acad Dermatol. 1989; 21: 205– 214. 48 Hunter GA, Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine. Br J Dermatol. 1972; 87: 42– 45. 49 Griffiths WAD. Pityriasis rubra pilaris. Clin Exp Dermatol. 1980; 5: 105– 112. 50 Munro DD. Azathioprine in psoriasis. Proc R Soc Med. 1973; 66: 747– 748. 51 Schoepf E, Schulz HJ, Schuiz KH. Azathiopdn-Behandlung der Dermatitis ulcerosa (pyoderma gangrenosum). Hautarzt. 1969; 20: 558– 563. 52 Olson K. Pyoderma gangrenosum with systemic LE. Acta Derm Venereol. 1971; 51: 233– 234. 53 August PG, Wells GC. Pyoderma gangrenosum treated with azathioprine and prednisone. Br J Dermatol. 1974; 91(suppl 10): 80– 82. 54 Byrne JPH, Hewitt M, Summerly R. Pyoderma gangrenosum associated with active chronic hepatitis. Arch Dermatol. 1976; 112: 1297– 1301. 55 Cohen PR, Rapini RP. Relapsing polychondritis. Int J Dermatol. 1986; 25: 280– 285. 56 Pacheco Y, Marechal C, Marechal F, et al. Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis. 1985; 2: 107– 113. 57 Winkelmann RK, Kierland RR, Perry HO, et al. Management of scleroderma. Mayo Clin Proc. 1971; 46: 128– 134. 58 Steigerwald JC. Progressive systemic sclerosis: management. III. Immunosuppressive agents. Clin Rheum Dis. 1979; 5: 284– 294. 59 Ahmed AR, Moy R. Azathioprine. Int J Dermatol. 1981; 20: 461– 467. 60 Cooper BJ, Bacal E, Patterson R. Allergic angiitis and granulomatosis: prolonged remission induced by combined prednisone-azathioprine therapy. Arch Intern Med. 1978; 138: 367– 371. 61 Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy for polyartedtis nodosa. Am J Med. 1979; 67: 941– 947. 62 Fauci AS, Haynes BF, Katz P, et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983; 98: 76– 85. 63 Yasue T. Livedoid vasculitis and central nervous system involvement in systemic lupus erythematosus. Arch Dermatol. 1986; 122: 66– 70. 64 Callen JP, Ekenstam E. Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients. South Med J. 1987; 80: 848– 851. 65 Rosman M, Bertino JR. Azathioprine. Ann Intern Med. 1973; 79: 694– 700. 66 Schein PS, Winokur SH. Immunosuppressive and cytotoxic chemotherapy: long term complications. Ann Intern Med. 1975; 82: 84– 95. 67 Speerstra F, Boerbooms AM, van de Putte LB, et al. Side effects of azathioprine treatment in rheumatoid arthritis: analysis of ten years of experience. Ann Rheum Dis. 1982; 41(suppl): 37– 39. 68 Saway PA, Heck LW, Bonner JR, et al. Azathioprine hypersensitivity: case report and review of the literature. Am J Med. 1988; 84: 960– 964. 69 Gebhardt DOE. Azathioprine teratogenicity: review of the literature and case report (letter). Obstet Gynecol. 1983; 61: 270. 70 Louis S, Schwartz RS. Immunodeficiency and the pathogenesis of lymphoma and leukemia. Semin Hematol. 1978; 15: 117– 138. 71 Krutchik AN, Buzdar AU, Tashima CK. Azathiopdne and breast carcinoma (letter). JAMA. 1978; 239: 107– 108. 72 McLelland J, Rees A, Williams G, et al. The incidence of immunosuppression-related skin disease in long-term transplant patients. Transplantation. 1988; 46: 871– 874. 73 Herskowitz LJ, Olansky S, Lang PG. Acute pancreatitis associated with long-term azathioprine therapy. Arch Dermatol. 1979; 115: 179. 74 Gendler E. Azathioprine for use in dermatology. J Dermatol Surg Oncol. 1984; 10: 462– 464. 75 Roper SS, Spraker MK. Cutaneous histiocytosis syndromes. Pediatr Dermatol. 1985; 3: 19– 30. 76 Hance AJ, Cadranel J, Soler P, et al. Systemic manifestations of pulmonary disease: pulmonary and extrapulmonary Langerhans' cell granulomatosis (histiocytosis X). Semin Resp Med. 1988; 9: 349– 368. 77 Kravetz RE, Balsam T. Treatment of psodasis with mercaptopurine. Arch Dermatol. 1961; 84: 597– 600. 78 Higgins LC Jr, Thompson JG. Psoriasis with arthritis: chemo therapy with cyclophosphamide, nitrogen mustard and 6-mer- captopurine. South Med J. 1966; 59: 1191– 1193. 79 Baum J, Hurch E, Lewis D, et al. Treatment of psoriatic arthritis with 6-mercaptopudne. Arthritis Rheum. 1973; 16: 139– 147. 80 Maldonado N, Torres VM, Mendez-Cashion D, et al. Pyoderma gangrenosum treated with 6-mercaptopurine and followed by acute leukemia. J Pediatr. 1968; 72: 409– 414. 81 Alper JC, Wiemann MC, Rueckl FS, et al. Rationally designed combination chemotherapy for the treatment of patients with recalcitrant psoriasis. J Am Acad Dermatol. 1985; 13: 567– 577. 82 Casas JA, Subauste CP, Alarcon GS. A promising treatment in systemic sclerosis: 5-fluorouracil. Ann Rheum Dis. 1987; 46: 763– 767. 83 Malaviya AN, Singh RR, Dhar A, et al. Correspondence: 5-fluorouracil in progressive systemic sclerosis: is it sale Ann Rheum Dis. 1988; 11: 964– 965. 84 Avant WH, HufF RC. Intradermal 5-fluorouracil in the treatment of basal cell carcinoma of the face. South Med J. 1976; 69: 561– 563. 85 Goette DK, Odom RB. Successful treatment of keratoacanthoma with intralesional fluorouracil. J Am Acad Dermatol. 1980; 2: 212– 216. 86 Kurtis B, Rosen T. Treatment of cutaneous neoplasms by intralesional injection of 5-fluorouracil. J Dermatol Surg Oncol. 1980; 6: 122– 127. 87 Odoni RB, Goette DK. Treatment of keratoacanthoma with intralesional 5-fluorouracil. Arch Dermatol. 1978; 114: 1779– 1783. 88 Bronner AK, Hood AF. Cutaneous complications of chemo- therapeutic agents. J Am Acad Dermatol. 1983; 9: 645– 663. 89 Lokich J, Moore C. Chemotherapy-associated palmarpiantar erythrodysesthesia syndrome. Ann Intern Med. 1984; 101: 798– 800. 90 Gershwin ME, Goetzl EJ, Steinberg AD. Cyclophosphamide: use in practice. Ann Intern Med. 1974; 80: 531– 540. 91 Ahmed AR, Hombal SM. Cyclophosphamide (Cytoxan). J Am Acad Dermatol. 1984; 11: 1115– 1126. 92 Buckeley CE III, Gillis JR Jr. Cyclophosphamide therapy of Behcet's disease. J Allergy Clin Immunol. 1969; 43: 273– 283. 93 Davatchi F, Baygan F, Chams H. et al. Cyclophosphamide in the treatment of the ocular manifestations of Behcet's disease. J Rheumatol. 1984; 11: 404– 405. 94 Ristow SC, Griner PF, Abraham GN, et al. Reversal of systemic manifestations of cryoglobulinemia: treatment with melphalan and prednisone. Arch Intern Med. 1976; 136: 467– 470. 95 El Ghobarch A, Balint GO. Dermatomyositis; observation on 119, the use of immunosuppressive therapy and review of literature. Postgrad Med. 1978; 54: 516– 527. 96 Yoshioka M, Okuno T, Mikawa H. Prognosis and treatment of 120, polymyositis with particular reference to steroid-resistant patients. Arch Dis Child. 1985; 60: 236– 244. 97 Bombardieri S, Hughes GRV, Neri R, et al. Cyclophosphamide in severe polymyositis (letter). Lancet. 1989; i: 1138– 1139. 98 Klein E, Hahn GM, Solomon JA, et al. Exploration of antimitotic agents in the treatment of a congenital disease, ichthyosis linearis circumflexa. J Surg Oncol. 1979; 11: 85– 88. 99 Jessen RT, Straight M, Becker LE. Lichen myxedematosus: treatment with cyclophosphamide. Int J Dermatol. 1978; 17: 833– 839. 100 Hecht B, Siegel N, Adler M, et al. Prognostic indices in lupus 124, nephritis. Medicine. 1976; 55: 163– 181. 101 McCune WJ, Golbus J, Zeldes W, et al. Clinical and immunological effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med. 1988; 318: 1423– 1431. 102 Brodell RT, Miller CW, Eisen AZ. Cutaneous lesions of lymphomatoid granulomatosis. Arch Dermatol, 1986; 122: 303– 306. 103 Brody HJ, Pirozzi DJ. Benign mucous membrane pemphigoid: 127, response to therapy with cyclophosphamide. Arch Dermatol. 1977; 113: 1598– 1599. 104 Ebringer A, Mackay IR. Pemphigus vulgaris successfully treated 128, with cyclophosphamide, Ann Intern Med. 1969; 71: 125– 127. 105 McKelvey EM, Hasegaga J. Cyclophosphamide and pemphigus vulgaris. Arch Dermatol. 1971; 103: 198– 200. 106 Fellner MJ, Katz JM, McCabe JB. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris. Arch Dermatol, 1978; 114: 889– 894. 107 Crawford SE, Sherman R, Farara B. Pyoderma gangrenosum with response to cyclophosphamide therapy. J Pediatr. 1967; 71: 255– 258. 109 Gabriel SE, Perry HO, Oleson GB, et al. Scleromyxedema: a seleroderma-like disorder with systemic manifestations. Medicine. 1988; 67: 58– 65. 110 Fauci AS, Katz P, Haynes BF, et al. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med. 1979; 301: 235– 238. 111 Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med. 1971; 284: 938– 942. 112 Morton CE, Easton DJ. Cytotoxic therapy for Wegener's granulomatosis (letter). Lancet. 1984; i: 1411. 113 DeRemee RA, McDonald TJ, Weiland LH. Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc. 1985; 60: 27– 32. 114 Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapy agents. Ann Intern Med. 1981; 94: 66– 72. 115 Kritharides L, Lawrie K, Varigos GA. Cyclophosphamide hypersensitivity and cross-reactivity with chlorambucil. Cancer Treat Rep. 1987; 71: 1323– 1324. 116 Mamo JG, Azzam SA. Treatment of Behcet's disease with chlorambucil. Arch Ophthalmol, 1970; 84: 446– 450. 117 Hamminga L, Hartgrink-Groenveld CA, van Vloten WA. Sezary's syndrome: a clinical evaluation of eight patients, Br J Dermatol. 1979; 100: 291– 296. 118 Finan MC, Winkelmann RK. Necrobiotic xanthogranuloma with paraproteinemia: a review of 22 cases. Medicine. 1986; 65: 376– 388. 119 Milligan A, Hutchinson PE. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol. 1990; 22: 796– 801. 120 Callen JP, Case JD, Sager D. Chlorambucil: an effective corticosteroid-sparing therapy for pyoderma gangrenosum. J Am Acad Dermatol. 1989; 21: 515– 519. 121 Kataria YP. Cblorambucil in sarcoidosis. Chest. 1980; 78: 36– 43. 122 Bradley JD, Brandt KD, Kath BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32: 45– 53. 123 Knisley RE, Settipane GA, Albala MM. Unusual reaction to chlorambucil in a patient with chronic lymphocytic leukemia. Arch Dermatol. 1971; 104: 77– 79. 124 Cameron S. Chlorambucil and leukemia (letter). N Engl J Med. 1977; 296: 1065. 125 Aymard JP, Frustin J, Witz F, et al. Acute leukemia after prolonged chlorambucil treatment for non-malignant disease: report of a new case and literature survey. Acta Haematol (Basel), 1980; 63: 283– 285. 126 Williams SA, Makker SP, Grupe WE. Seizures: a significant side effect of chlorambucil therapy in children, J Pediatr. 1978; 93: 516– 518. 127 Reimer RR, Hoover R, Fraumeni JF, et al. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med. 1977; 297: 177– 181. 128 Kyle RA, Greipp PR, Garton JP, et al. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985; 79: 708– 716. 129 Benson MD. Treatment of AL amyloidosis with melphalan, prednisone, and colchicine. Arthritis Rheum. 1986; 29: 683– 687. 130 Lazarus HM, Herzig RH, Wolff SN, et al. Treatment of meta-static melanoma with intensive melphalan and autologous bone marrow transplantation. Cancer Treat Rep, 1985; 69: 473– 477. 131 Moeller H, Waldenstroem JG, Zettervall O. Pyoderma gangrenosum (dermatitis ulcerosa) and monoclonal (igA) globulin healed after melphalan treatment: case report and review of the literature. Acta Med Scand. 1978; 203: 293– 296. 132 Wright RC, Franco RS, Denton MD, et al. Scleromyxedema. Arch Dermatol. 1976; 112: 63– 66. 133 Harris RB, Perry HO, Kyle RA, et al. Treatment of scleromyxedema with melphalan. Arch Dermatol. 1979; 115: 295– 299. 134 Einhorn N. Acute leukemia after chemotherapy (melphalan). Cancer. 1978; 41: 444– 447. 135 Westerfield BT, Michalski JP, McCombs C, Light RW. Reversible melphalan-induced lung damage. Am J Med. 1980; 68: 767– 771. 136 Kellie SJ, Plowman PN, Malpas JS. Radiation recall and radio-sensitization with alkylating agents (letter). Lancet. 1987; i: 1149– 1150. 137 Tucker SB, Winkelmann RK. Treatment of Kaposi sarcoma with vinblastine. Arch Dermatol. 1976; 112: 958– 961. 138 Klein E, Schwartz RA, Laor Y, et al. Treatment of Kaposi's sarcoma with vinblastine. Cancer. 1980; 45: 427– 431. 139 Mintzer DM, Real FX, Jovino L, Krown SE. Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome. Ann In tern Med. 1985; 102: 200– 202. 140 Volberding PA, Abrams DI, Conant M, Kaslow K, Ziegler J. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med. 1985; 103: 335– 338. 141 Kaplan L, Abrams D, Volberding P. Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat Rep. 1986; 70: 1121– 1122. 142 Volberding PA. The role of chemotherapy for epidemic Kaposi's sarcoma. Semin Oncol. 1987; 14: 23– 26. 143 Gelmann EP, Longo D, Lane HC, et al. Combination chemo therapy of disseminated Kaposi's sarcoma in patients with the acquired immune deficiency syndrome. Am J Med. 1987; 82: 456– 462. 144 Odom RB. Intralesional vincdstine “effective” in Kaposi's. Dermatol News. 1987; 20: 1. 145 Shelley WB, Shelley ED. Erythema annulare centrifugum as the presenting sign of the hypereosinophilic syndrome: observations on therapy. Cutis. 1985; 35: 53– 55. 146 Leavell UW, Yarbro JW. Hydroxyurea: a new treatment for psoriasis. Arch Dermatol. 1970; 102: 144– 150. 147 Moschella SL, Greenwald MA. Psoriasis with hydroxyurea: an 18-month study of 60 patients. Arch Dermatol. 1973; 107: 363– 368. 148 Leavell UW, Mersack IP, Smith C. Survey of the treatment of psoriasis with hydroxyurea (letter). Arch Dermatol. 1973; 107: 467. 149 Smith C, Gelfant S. Effects of methotrexate and hydroxyurea on psoriatic epidermis: preferential cytotoxic effects on psoriatic epidermis. Arch Dermatol. 1974; 110: 70– 72. 150 Kennedy BJ, Smith LR. Skin changes secondary to hydroxyurea therapy. Arch Dermatol. 1975; 111: 183– 187. Citing Literature Volume30, Issue5May 1991Pages 313-322 ReferencesRelatedInformation